Continue to site >
Trending ETFs

iShares U.S. Pharmaceuticals ETF

ETF
IHE
Payout Change
Pending
Price as of:
$188.83 +2.22 +1.19%
primary theme
Health Care Sector Equity
IHE (ETF)

iShares U.S. Pharmaceuticals ETF

Payout Change
Pending
Price as of:
$188.83 +2.22 +1.19%
primary theme
Health Care Sector Equity
IHE (ETF)

iShares U.S. Pharmaceuticals ETF

Payout Change
Pending
Price as of:
$188.83 +2.22 +1.19%
primary theme
Health Care Sector Equity

Name

Price

Aum/Mkt Cap

YIELD & DIV

Exp Ratio

Watchlist

$188.83

$395 M

1.68%

$3.17

0.42%

Vitals

YTD Return

-7.1%

1 yr return

6.6%

3 Yr Avg Return

9.6%

5 Yr Avg Return

5.7%

Net Assets

$395 M

Holdings in Top 10

80.5%

52 WEEK LOW AND HIGH

$186.6
$180.80
$201.82

Expenses

OPERATING FEES

Expense Ratio 0.42%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover 52.00%

Redemption Fee N/A


Min Investment

Standard (Taxable)

N/A

IRA

N/A


Fund Classification

Fund Type

Exchange Traded Fund

Investment Style

Health


Name

Price

Aum/Mkt Cap

YIELD & DIV

Exp Ratio

Watchlist

$188.83

$395 M

1.68%

$3.17

0.42%

IHE - Profile

Distributions

  • YTD Total Return -5.4%
  • 3 Yr Annualized Total Return 9.6%
  • 5 Yr Annualized Total Return 5.7%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio 1.33%
DIVIDENDS
  • Dividend Yield 1.7%
  • Dividend Distribution Frequency Quarterly

Fund Details

  • Legal Name
    iShares U.S. Pharmaceuticals ETF
  • Fund Family Name
    iShares
  • Inception Date
    May 01, 2006
  • Shares Outstanding
    2100000
  • Share Class
    N/A
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Greg Savage

Fund Description

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index measures the performance of the pharmaceuticals sector of the U.S. equity market. The underlying index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins. The fund is non-diversified.


IHE - Performance

Return Ranking - Trailing

Period IHE Return Category Return Low Category Return High Rank in Category (%)
YTD -7.1% -38.7% 25.3% 22.62%
1 Yr 6.6% -61.5% 33.9% 15.58%
3 Yr 9.6%* -7.4% 20.2% 63.76%
5 Yr 5.7%* -6.1% 17.2% 81.82%
10 Yr 10.0%* 5.8% 17.9% 92.86%

* Annualized

Return Ranking - Calendar

Period IHE Return Category Return Low Category Return High Rank in Category (%)
2021 11.3% -79.9% 25.9% 21.86%
2020 12.1% -13.6% 178.2% 58.64%
2019 13.8% 3.8% 63.8% 88.97%
2018 -8.8% -49.7% 21.5% 64.23%
2017 9.2% -59.8% 54.4% 81.48%

Total Return Ranking - Trailing

Period IHE Return Category Return Low Category Return High Rank in Category (%)
YTD -5.4% -49.2% 25.3% 20.36%
1 Yr 6.6% -61.5% 31.1% 22.97%
3 Yr 9.6%* -15.9% 20.2% 61.67%
5 Yr 5.7%* -7.4% 17.2% 81.61%
10 Yr 10.0%* 5.8% 17.9% 92.65%

* Annualized

Total Return Ranking - Calendar

Period IHE Return Category Return Low Category Return High Rank in Category (%)
2021 11.3% -79.9% 25.9% 21.86%
2020 12.1% -13.6% 178.2% 58.64%
2019 13.8% 3.8% 63.8% 88.97%
2018 -8.8% -49.7% 22.2% 66.42%
2017 9.2% -59.8% 54.4% 90.37%

IHE - Holdings

Concentration Analysis

IHE Category Low Category High IHE % Rank
Net Assets 395 M 561 K 46.5 B 53.01%
Number of Holdings 49 11 476 66.67%
Net Assets in Top 10 317 M 2.18 K 21.5 B 36.63%
Weighting of Top 10 80.45% 11.7% 94.7% 1.23%

Top 10 Holdings

  1. Johnson & Johnson 23.69%
  2. Pfizer Inc 20.36%
  3. Horizon Therapeutics PLC 6.38%
  4. Horizon Therapeutics PLC 6.38%
  5. Horizon Therapeutics PLC 6.38%
  6. Horizon Therapeutics PLC 6.38%
  7. Horizon Therapeutics PLC 6.38%
  8. Horizon Therapeutics PLC 6.38%
  9. Horizon Therapeutics PLC 6.38%
  10. Horizon Therapeutics PLC 6.38%

Asset Allocation

Weighting Return Low Return High IHE % Rank
Stocks
99.86% 86.21% 105.95% 37.86%
Cash
0.14% -0.64% 9.01% 58.44%
Preferred Stocks
0.00% 0.00% 7.86% 47.74%
Other
0.00% -21.78% 3.00% 51.44%
Convertible Bonds
0.00% 0.00% 0.32% 46.91%
Bonds
0.00% 0.00% 12.66% 45.27%

Stock Sector Breakdown

Weighting Return Low Return High IHE % Rank
Healthcare
100.00% 59.26% 100.00% 27.57%
Utilities
0.00% 0.00% 0.00% 44.03%
Technology
0.00% 0.00% 22.69% 48.56%
Real Estate
0.00% 0.00% 6.79% 48.15%
Industrials
0.00% 0.00% 7.02% 47.74%
Financial Services
0.00% 0.00% 1.84% 57.61%
Energy
0.00% 0.00% 0.00% 44.03%
Communication Services
0.00% 0.00% 9.11% 46.91%
Consumer Defense
0.00% 0.00% 26.69% 50.62%
Consumer Cyclical
0.00% 0.00% 14.58% 47.74%
Basic Materials
0.00% 0.00% 15.33% 60.49%

Stock Geographic Breakdown

Weighting Return Low Return High IHE % Rank
US
99.74% 53.13% 103.53% 7.41%
Non US
0.12% 0.00% 45.28% 93.00%

IHE - Expenses

Operational Fees

IHE Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.42% 0.08% 3.13% 66.11%
Management Fee 0.42% 0.00% 1.25% 13.11%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee N/A 0.03% 0.25% N/A

Sales Fees

IHE Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 0.00% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

IHE Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 2.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

IHE Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 52.00% 0.00% 256.00% 62.42%

IHE - Distributions

Dividend Yield Analysis

IHE Category Low Category High IHE % Rank
Dividend Yield 1.68% 0.00% 4.26% 4.55%

Dividend Distribution Analysis

IHE Category Low Category High Category Mod
Dividend Distribution Frequency Quarterly Annually Monthly Semi-Annually

Net Income Ratio Analysis

IHE Category Low Category High IHE % Rank
Net Income Ratio 1.33% -2.54% 1.92% 4.07%

Capital Gain Distribution Analysis

IHE Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually

Dividend Payout History

View More +

IHE - Fund Manager Analysis

Managers

Greg Savage


Start Date

Tenure

Tenure Rank

Jan 01, 2008

14.34

14.3%

Greg Savage, Managing Director; has been associated with BlackRock Fund Advisors since 2009. Mr. Savage has been a senior portfolio manager for BFA and BTC since 2009. Prior to his employment with BFA and BTC, Mr. Savage was a senior portfolio manager from 2006 to 2009 for BGFA and BGI and a portfolio manager from 2001 to 2006 for BGFA and BGI.

Jennifer Hsui


Start Date

Tenure

Tenure Rank

Sep 01, 2012

9.67

9.7%

Jennifer Hsui, Managing Director & Portfolio Manager at BlackRock Investment Management LLC has been employed by BlackRock Fund Advisors as a senior portfolio manager since 2007. Prior to that, Ms. Hsui was a portfolio manager from 2006 to 2007 for BGFA. She was a research analyst for RBC Capital Markets from 2003 to 2006.

Amy Whitelaw


Start Date

Tenure

Tenure Rank

Aug 01, 2018

3.75

3.8%

Amy Whitelaw is Managing Director of BlackRock, Inc. since 2013 and was Director of the firm from 2009 to 2012. Ms. Whitelaw's service with the firm dates back to 1998, including her years with Barclays Global Investors (BGI), which merged with BlackRock in 2009. Ms. Whitelaw served as Principal of BGI from 2000 to 2009. Previously Ms. Whitelaw worked in the Transition Services group as a transition manager and strategist, and was also an international equity trader on BGI’s trading desk.

Paul Whitehead


Start Date

Tenure

Tenure Rank

Jan 01, 2022

0.33

0.3%

Paul Whitehead is responsible for supporting the day-to-day management of the MML Blend Fund’s portfolio, including setting the Fund’s overall investment strategy and overseeing the management of the Fund. Mr. Whitehead is a Managing Director of BlackRock, Inc., Co-Head of Index Equity, and Co-Head of BlackRock’s ETF and Index Investments business. Mr. Whitehead also oversees the management of BlackRock’s Institutional and iShares funds. Mr. Whitehead was previously the Global Head of Equity Trading and the Global Head of Transition Management within BlackRock’s Global Trading Group. Mr. Whitehead’s service with the firm dates back to 1996, including his years with Barclays Global Investors, which merged with BlackRock in 2009. Prior to his current role, Mr. Whitehead was Head of Americas Equity Trading. Previously, he managed the trading team responsible for all Institutional Index funds, Exchange Traded funds, and Transition Management mandates. Mr. Whitehead represents BlackRock on the board of Luminex, a buy-side owned Alternative Trading System launched in 2015.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.08 24.64 6.59 2.04